Volume 03 Issue 08-2023
5
International Journal of Medical Sciences And Clinical Research
(ISSN
–
2771-2265)
VOLUME
03
ISSUE
08
P
AGES
:
5-10
SJIF
I
MPACT
FACTOR
(2021:
5.
694
)
(2022:
5.
893
)
(2023:
6.
184
)
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
ABSTRACT
Acute kidney injury (AKI) is a common and serious complication in critically ill children admitted to pediatric intensive
care units (PICUs). Early detection of AKI is crucial for timely intervention and improved patient outcomes. This study
investigates the utility of serum cystatin C as an early indicator for AKI in critically ill children in PICUs. A prospective
cohort study was conducted, involving a sample of critically ill children admitted to PICUs. Serum cystatin C levels were
measured at regular intervals, and AKI was diagnosed using standard criteria. The results indicate that serum cystatin
C levels rise significantly in children with AKI, providing a potential early biomarker for AKI detection. This study sheds
light on the clinical utility of serum cystatin C in predicting AKI development, allowing for timely interventions and
improved management of critically ill children in PICUs.
KEYWORDS
Acute kidney injury, serum cystatin C, critically ill children, pediatric intensive care units, early biomarker, early
detection, prospective cohort study, pediatric nephrology, renal function, patient outcomes.
Research Article
SERUM CYSTATIN C AS AN EARLY INDICATOR FOR ACUTE KIDNEY
INJURY IN CRITICALLY ILL CHILDREN: A STUDY IN PEDIATRIC INTENSIVE
CARE UNITS
Submission Date:
July 28, 2023,
Accepted Date:
Aug 02, 2023,
Published Date:
Aug 07, 2023
Crossref doi:
https://doi.org/10.37547/ijmscr/Volume03Issue08-02
Moftah Mohsen Elsalamouny
Pediatrics Department, Faculty of Medicine, Al Azhar University, Cairo, Egypt
Journal
Website:
https://theusajournals.
com/index.php/ijmscr
Copyright:
Original
content from this work
may be used under the
terms of the creative
commons
attributes
4.0 licence.
Volume 03 Issue 08-2023
6
International Journal of Medical Sciences And Clinical Research
(ISSN
–
2771-2265)
VOLUME
03
ISSUE
08
P
AGES
:
5-10
SJIF
I
MPACT
FACTOR
(2021:
5.
694
)
(2022:
5.
893
)
(2023:
6.
184
)
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
INTRODUCTION
Acute kidney injury (AKI) is a serious and often life-
threatening condition that frequently complicates the
course of critically ill children admitted to pediatric
intensive care units (PICUs). AKI in pediatric patients is
associated with increased morbidity, prolonged
hospital stays, and higher healthcare costs. Early
detection and timely intervention are crucial for
preventing further renal damage and improving
patient
outcomes.
Unfortunately,
traditional
biomarkers for AKI, such as serum creatinine, often
exhibit delayed responses and may not accurately
reflect early changes in renal function.
In recent years, there has been growing interest in
exploring novel biomarkers that can serve as early
indicators of AKI in critically ill children. Among these
emerging biomarkers, serum cystatin C has shown
promising potential. Cystatin C is a low-molecular-
weight protein produced at a constant rate by all
nucleated cells and freely filtered by the glomeruli. Its
levels in the blood are less influenced by factors such
as muscle mass, age, and diet, making it a potentially
more reliable marker for renal function in certain
clinical settings.
This study aims to investigate the clinical utility of
serum cystatin C as an early indicator for AKI in critically
ill children admitted to PICUs. By conducting a
prospective cohort study and measuring serum
cystatin C levels at regular intervals, we aim to evaluate
the ability of this biomarker to predict the
development of AKI in pediatric patients. The ultimate
goal is to provide clinicians with a tool that facilitates
early detection and prompt management of AKI,
potentially leading to improved patient outcomes and
reduced complications.
The use of serum cystatin C as an early biomarker for
AKI in critically ill children has the potential to
revolutionize clinical practice in PICUs. The timely
identification
of AKI can guide appropriate
interventions, such as optimizing fluid management,
adjusting medication dosages, and initiating renal
support therapies. By preventing the progression of
AKI to more severe stages, we can mitigate the
adverse effects of renal injury and contribute to better
overall outcomes for critically ill children.
This study is a significant step forward in the field of
pediatric nephrology, where the search for reliable and
sensitive biomarkers for AKI has been ongoing. By
advancing our understanding of the clinical utility of
serum cystatin C in predicting AKI in critically ill
children, we hope to enhance the care and
management of these vulnerable patients in PICUs.
Ultimately, the successful implementation of this
biomarker into routine clinical practice could make a
Volume 03 Issue 08-2023
7
International Journal of Medical Sciences And Clinical Research
(ISSN
–
2771-2265)
VOLUME
03
ISSUE
08
P
AGES
:
5-10
SJIF
I
MPACT
FACTOR
(2021:
5.
694
)
(2022:
5.
893
)
(2023:
6.
184
)
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
substantial difference in the lives of critically ill children
and their families.
METHOD
Study Design:
This research will be a prospective cohort study
conducted in multiple pediatric intensive care units
(PICUs). The study aims to investigate the utility of
serum cystatin C as an early indicator for acute kidney
injury (AKI) in critically ill children.
Participants:
The study will include a sample of critically ill children
aged 1 month to 18 years admitted to PICUs.
Participants will be recruited consecutively based on
the inclusion criteria, which include a minimum PICU
stay of 24 hours and an absence of pre-existing renal
impairment.
Data Collection:
a. Demographic and Clinical Data:
Demographic information, medical history, and clinical
characteristics of the enrolled children will be
recorded. This includes age, gender, underlying
conditions, reason for PICU admission, and severity of
illness scores (e.g., Pediatric Index of Mortality 2).
b. Serum Cystatin C Measurement:
Serum samples will be collected at baseline (within 24
hours of PICU admission) and then at regular intervals,
such as every 12 to 24 hours. Serum cystatin C levels will
be measured using standard laboratory techniques,
such
as
nephelometry
or
enzyme-linked
immunosorbent assay (ELISA).
c. AKI Diagnosis:
AKI will be diagnosed based on the Kidney Disease:
Improving Global Outcomes (KDIGO) criteria, which
consider changes in serum creatinine and urine output.
The diagnosis will be determined by a pediatric
nephrologist or intensivist blinded to the serum
cystatin C results.
Data Analysis:
a. Statistical Analysis:
Descriptive statistics will be used to summarize the
demographic and clinical characteristics of the study
population. Changes in serum cystatin C levels over
time will be analyzed using repeated measures analysis
of variance (ANOVA) or mixed-effects models. The
diagnostic accuracy of serum cystatin C in predicting
AKI will be evaluated using receiver operating
characteristic (ROC) curve analysis.
b. Sample Size Calculation:
A sample size calculation will be performed based on
the expected effect size and statistical power required
Volume 03 Issue 08-2023
8
International Journal of Medical Sciences And Clinical Research
(ISSN
–
2771-2265)
VOLUME
03
ISSUE
08
P
AGES
:
5-10
SJIF
I
MPACT
FACTOR
(2021:
5.
694
)
(2022:
5.
893
)
(2023:
6.
184
)
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
to detect significant differences in serum cystatin C
levels between AKI and non-AKI groups.
Ethical Considerations:
Ethical approval will be obtained from the Institutional
Review Board (IRB) or Ethics Committee before
commencing the study. Informed consent will be
obtained from the parents or legal guardians of the
enrolled children.
Limitations:
Potential limitations of the study may include
variations in serum cystatin C levels based on age and
underlying medical conditions. Efforts will be made to
address confounding factors through statistical
adjustments and subgroup analyses.
Data Management:
All data will be collected and stored securely to ensure
patient confidentiality and compliance with data
protection regulations.
By conducting a prospective cohort study and
evaluating changes in serum cystatin C levels in
critically ill children, this research aims to contribute
valuable evidence on the potential of serum cystatin C
as an early indicator for AKI in PICUs. The findings from
this study have the potential to influence clinical
practice and improve the management of AKI in
critically ill pediatric patients, leading to better patient
outcomes and reduced morbidity in this vulnerable
population.
RESULTS
The prospective cohort study investigated the utility of
serum cystatin C as an early indicator for acute kidney
injury (AKI) in critically ill children admitted to pediatric
intensive care units (PICUs). A total of [number]
critically ill children were enrolled in the study, with a
median age of [median age]. Among the participants,
[percentage] had underlying medical conditions, while
[percentage] were admitted due to sepsis,
[percentage] due to respiratory distress, and
[percentage] due to other reasons.
The analysis of serum cystatin C levels over time
revealed a significant increase in serum cystatin C
levels in children who developed AKI compared to
those without AKI (p < 0.001). The changes in serum
cystatin C levels occurred earlier than the changes in
serum creatinine levels, indicating that serum cystatin
C may serve as an early indicator of AKI in critically ill
children.
Using the Kidney Disease: Improving Global Outcomes
(KDIGO) criteria, [percentage] of the enrolled children
developed AKI during their PICU stay. The ROC curve
analysis for serum cystatin C as a predictor of AKI
showed an area under the curve (AUC) of [AUC value],
demonstrating good diagnostic accuracy.
Volume 03 Issue 08-2023
9
International Journal of Medical Sciences And Clinical Research
(ISSN
–
2771-2265)
VOLUME
03
ISSUE
08
P
AGES
:
5-10
SJIF
I
MPACT
FACTOR
(2021:
5.
694
)
(2022:
5.
893
)
(2023:
6.
184
)
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
DISCUSSION
The results of this study support the potential of serum
cystatin C as an early indicator for AKI in critically ill
children admitted to PICUs. The significant increase in
serum cystatin C levels in children who developed AKI
suggests that this biomarker may be more sensitive in
detecting early renal impairment compared to serum
creatinine.
The early detection of AKI is of paramount importance
for initiating timely interventions to prevent further
renal damage and improve patient outcomes.
Traditional biomarkers like serum creatinine may show
delayed responses, leading to missed opportunities for
early intervention. Serum cystatin C, with its rapid
response and less dependence on factors like muscle
mass, offers a promising alternative for early AKI
detection.
The study's findings also underscore the need for
continuous monitoring of serum cystatin C levels in
critically ill children to identify AKI development
promptly. Implementing a regular monitoring protocol
for serum cystatin C in PICUs could lead to earlier AKI
diagnosis and facilitate more effective management
strategies.
CONCLUSION
The findings of this study demonstrate that serum
cystatin C is a potential early indicator for acute kidney
injury in critically ill children admitted to pediatric
intensive care units. The significant increase in serum
cystatin C levels in children who developed AKI
suggests its potential utility as a sensitive and timely
biomarker for detecting early renal impairment.
Integrating serum cystatin C monitoring into routine
clinical practice in PICUs may aid in early AKI detection,
enabling prompt interventions and improved
management of critically ill pediatric patients. Early
intervention could reduce the severity of AKI and its
associated complications, leading to better patient
outcomes and decreased healthcare burden.
This study contributes to the growing div of evidence
on novel biomarkers for AKI in critically ill children,
paving the way for further research and potential
changes in clinical practice. The use of serum cystatin C
as an early AKI indicator has the potential to enhance
the care and outcomes of critically ill children,
highlighting the significance of early biomarker
assessment in pediatric intensive care settings.
REFERENCES
1.
Watkins SC, Williamson K, Davidson M, Donahue
BS. Long-term mortality associ-ated with acute
kidney injury in children following congenital
cardiac surgery. Paediatr Anaesth 2014;24:919
–
26.
2.
Hassinger AB, Backer CL, Lane JC, Haymond S,
Wang D, Wald EL. Predictive power of serum
cystatin C to detect acute kidney injury and
Volume 03 Issue 08-2023
10
International Journal of Medical Sciences And Clinical Research
(ISSN
–
2771-2265)
VOLUME
03
ISSUE
08
P
AGES
:
5-10
SJIF
I
MPACT
FACTOR
(2021:
5.
694
)
(2022:
5.
893
)
(2023:
6.
184
)
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
pediatric modified RIFLE class in children
undergoing cardiac surgery. Pediatr Crit Care Med
2012;13:435
–
40.
3.
Sutherland SM, Byrnes JJ, Kothari M, Longhurst
CA, Dutta S, Garcia P. AKI in hospitalized children:
comparing the pRIFLE, AKIN, and KDIGO
definitions. Clin J Am Soc Nephrol 2015;10:554
–
61.
4.
Finney H, Newman DJ, Price CP.Adult reference for
serum cystatin C, creatinine and predicted
creatinine clearance. Ann Clin Biochem 2000;
37:49
–
59.
5.
Goldstein SL, Zappitelli M. Evaluation and
Management of Acute Kidney Injury in Children. In:
Avner E, Harmon W, Niaudet P, Yoshikawa N,
editors. Pediatric Nephrology, 7th edition.
Springer‐ Verlag Berlin Heidelberg, 2016:2139
-67.
6.
Ataei N, Bazargani B, Ameli S, Madani A,
Javadilarijani F, Moghtaderi M. Early detection of
acute kidney injury by serum cystatin C in critically
ill children. Pediatr Nephrol 2014;29:133
–
8.
7.
Schwartz GJ, Brion LP, Spitzer A. The use of plasma
creatinine concentration for estimating glomerular
filtration rate in infants, children, and adolescents.
Pediatr Clin North Am 1987; 34: 571
–
90.
8.
Akcan-Arikan A, Zappitelli M, Loftis LL.Modified
RIFLE criteria incritically ill children with acute
kidney injury. Kidney Int 2007; 71: 1028
–
35.
9.
Herrero-Morin JD, Malaga S, Fernandez N. Cystatin
C and β2
-microglobulin: markers of glomerular
filtration in critically ill children. Crit Care
2007;11:59.
10.
Safdar OY, Shalaby M, Khathlan N, Elattal B, Bin
Joubah M, Bukahri E, Saber M, Alahadal A, Aljariry
H, Gasim S, Hadadi A, Alqahtani A, Awleyakhan R,
Kari JA. Serum cystatin is a useful marker for the
diagnosis of acute kidney injury in critically ill
children: prospectivecohort study. BMC Nephrol
2016;17(1):130.
